2-异丙基-3,6-二甲氧基-5-甲基-2,5-二氢吡嗪 | 207923-14-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 甲亚胺酸及其衍生物
• 中文名称: 2-异丙基-3,6-二甲氧基-5-甲基-2,5-二氢吡嗪
• 英文名称: (6R)-6-isopropyl-5-methoxy-3-methyl-3,6-dihydro-2-pyrazinyl methyl ether
• 英文别名: (2R,5SR)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-5-methylpyrazine；(2R,5S/R)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-5-methylpyrazine；(2R,5RS)-2-isopropyl-3,6-dimethoxy-5-methyl-2,5-dihydropyrazine；(2R,5SR)-2-isopropyl-3,6-dimethoxy-5-methyl-2,5-dihydropyrazine；(2R)-2-isopropyl-3,6-dimethoxy-5-methyl-2,5-dihydropyrazine；(5R)-3,6-dimethoxy-2-methyl-5-isopropyl-2,5-dihydropyrazine；(R)-(-)-2,5-dihydro-3,6-dimethoxy-2-isopropyl-5-methylpyrazine；(5R)-3,6-dimethoxy-2-methyl-5-propan-2-yl-2,5-dihydropyrazine
• CAS: 207923-14-6
• 化学式: C₁₀H₁₈N₂O₂
• 分子量: 198.265
• InChiKey: AGSVBAIKOLJRNR-BRFYHDHCSA-N

物化性质

• 沸点：
  256.5±33.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  43.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-异丙基-3,6-二甲氧基-5-甲基-2,5-二氢吡嗪 在 1,3-二甲基-2-咪唑啉酮 、 盐酸 、 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 、 乙腈 为溶剂， 反应 30.0h， 生成 D-Valine methyl ester
  参考文献：
  名称：

  Stereoselective synthesis of α,α′-bridged bis(α-alanine) derivatives

  摘要：

  Stereoselective syntheses of alpha,alpha'-dimethylated C-2-C-4 alkylene-bridged bis(glycine) methyl esters are described. The products were further converted into N-Fmoc-protected bis(amino acids). (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(98)00208-7
• 作为产物：
  描述：

  (R)-2,5-二氢-3,6-二甲氧基-2-异丙基吡嗪 、 碘甲烷 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 3.5h， 以80.5%的产率得到2-异丙基-3,6-二甲氧基-5-甲基-2,5-二氢吡嗪
  参考文献：
  名称：

  [EN] STAPLED AND STITCHED POLYPEPTIDES AND USES THEREOF
  [FR] POLYPEPTIDES À AGRAFES ET À SUTURE ET LEURS UTILISATIONS

  摘要：

  本发明提供了Formulae (I)和(VI)的订书钉多肽：(I) (VI)及其盐；其中的基团=====；R1a、R1b、R1c、R2a、R3a、R2b、R3b、R4a、R4b、RA、RZ、L1a、L1b、L2、L3、XAA、v、w、p、m、s、n、t和q如本文所定义。本发明还提供了从未定书钉的多肽前体制备创新的定书钉多肽的方法。本发明还提供了包含Formula (I)或(VI)的定书钉多肽的药物组合物，以及使用这些定书钉肽的方法。本发明还提供了环闭合交换反应后订书钉的修饰。

  公开号：

  WO2014159969A1

文献信息

• 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES
  申请人：Galley Guido

  公开号：US20100029589A1

  公开（公告）日：2010-02-04

  The invention relates to compounds of formula I wherein R 1 , R 2 , X, Y, and n are defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention also provides pharmaceutical compositions and methods of manufacture of such compounds. The compounds are useful for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases are depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及公式I的化合物，其中R1、R2、X、Y和n在规范中定义，并且其药学上可接受的酸盐。该发明还提供了制备这种化合物的药物组合物和方法。这些化合物可用于治疗与痕量胺相关受体的生物功能相关的疾病，这些疾病包括抑郁症、焦虑症、躁郁症、注意缺陷多动障碍、与压力有关的疾病、精神疾病、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢紊乱、进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收异常、体温稳态异常、睡眠和昼夜节律异常、心血管疾病。
• P38 inhibitors and methods of use thereof
  申请人：Munson Mark

  公开号：US20060264431A1

  公开（公告）日：2006-11-23

  Inhibitors of p38 and methods for producing these inhibitors are provided. Also provided are pharmaceutical compositions comprising the inhibitors of the invention, methods of utilizing the inhibitors and pharmaceutical compositions comprising said inhibitors in the treatment and prevention of various disorders mediated by p38, and kits comprising said inhibitors.

  提供p38的抑制剂和制备这些抑制剂的方法。还提供了包括该发明的抑制剂的药物组合物、利用这些抑制剂和药物组合物治疗和预防由p38介导的各种疾病的方法，以及包括这些抑制剂的试剂盒。
• Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists
  作者：Guido Galley、Angélica Beurier、Guillaume Décoret、Annick Goergler、Roman Hutter、Susanne Mohr、Axel Pähler、Philipp Schmid、Dietrich Türck、Robert Unger、Katrin Groebke Zbinden、Marius C. Hoener、Roger D. Norcross

  DOI：10.1021/acsmedchemlett.5b00449

  日期：2016.2.11

  ligands. Starting from a known adrenergic compound 1, structural modifications were made to obtain highly potent and selective TAAR1 ligands such as 12 (RO5166017), 18 (RO5256390), 36 (RO5203648), and 48 (RO5263397). These compounds exhibit drug-like physicochemical properties, have good oral bioavailability, and display in vivo activity in a variety of animal models relevant for psychiatric diseases

  发现2-氨基恶唑啉是TAAR1配体的新型结构类别。从已知的肾上腺素化合物1开始，进行了结构修饰，以获得高效且选择性的TAAR1配体，例如12（RO5166017），18（RO5256390），36（RO5203648）和48（RO5263397）。这些化合物表现出类似药物的理化性质，具有良好的口服生物利用度，并且在与精神疾病和成瘾有关的多种动物模型中显示出体内活性。
• DIPHENYL SULFIDE DERIVATIVES AND MEDICINES CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：Kohno Yasushi

  公开号：US20120101068A1

  公开（公告）日：2012-04-26

  Provided are diphenyl sulfide derivatives which have excellent S1P3 antagonistic activity and are useful as drugs. Intensive studies have been made for the purpose of creating a compound having S1P3 antagonistic activity. As a result of the intensive studies, it has been found that diphenyl sulfide derivatives represented by general formula (1) have excellent S1P3 antagonistic activity. In general formula (1), R 1 is a hydrogen atom or the like; R 2 is an optionally substituted alkyl group having 1 to 6 carbon atoms, or the like; X is a methylene group which may be substituted with one or two fluorine atoms, or the like; Y is a hydrogen atom or the like; and Z is a halogen atom.

  提供了具有优异S1P3拮抗活性并且可用作药物的二苯基硫醚衍生物。为了创造具有S1P3拮抗活性的化合物，进行了深入研究。经过深入研究，发现由通式（1）表示的二苯基硫醚衍生物具有优异的S1P3拮抗活性。在通式（1）中，R1是氢原子或类似物；R2是具有1至6个碳原子的可选择取代的烷基基团或类似物；X是一个甲基基团，可能被一个或两个氟原子取代，或类似物；Y是氢原子或类似物；Z是卤素原子。
• Asymmetric Synthesis and Conformational Analysis by NMR Spectroscopy and MD of Aba- and α-MeAba-Containing Dermorphin Analogues
  作者：Bart Vandormael、Rien De Wachter、José C. Martins、Pieter M. S. Hendrickx、Attila Keresztes、Steven Ballet、Jayapal R. Mallareddy、Fanni Tóth、Géza Tóth、Dirk Tourwé

  DOI：10.1002/cmdc.201100314

  日期：2011.11.4

  ee. [(S)‐Aba 3‐Gly 4]dermorphin retained μ‐opioid affinity but displayed an increased δ‐affinity. The corresponding R epimer was considerably less potent. In contrast, the [(R)‐α‐MeAba 3‐Gly 4]dermorphin isomer was more potent than its S epimer. Tar‐MD simulations of both non‐methylated [Aba 3‐Gly 4]dermorphin analogues showed a degree of folding at the C‐terminal residues toward the N terminus of the

  含有（S）-和（R）-4-氨基-1,2,4,5-四氢-2-苯并ze庚因-3-酮骨架（Aba）和α-甲基化类似物作为构象受限的苯丙氨酸的Dermorphin类似物，准备好了。不对称相转移催化无法提供（小号）-α-ME- ø -cyanophenylalanine前体（小号）-α-MeAba在可接受的对映体纯度。但是，通过使用Schöllkopf手性助剂，该中间体的收率为88％ee。[（S）‐Aba 3-Gly 4] dermorphin保留了μ阿片样物质的亲和力，但显示出增加的δ-亲和力。相应的R 差向异构体的效力明显较低。相反，[（R）-α-MeAba3-Gly 4] dermorphin异构体比其S 差向异构体更有效。两种未甲基化的[Aba 3–Gly 4] dermorphin类似物的Tar–MD模拟显示，在C端残基朝着肽的N端折叠了一定程度，但是没有采用稳定的β-转角构象。所述α甲基化的类似物，在另一方面，显示出类型I